Attovia Therapeutics, Inc.
ATTO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002058707
In the last 90 days, Attovia Therapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 65 institutions reported holding it in 13F filings for Q3 2026, worth $693.4M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 20, 2026
- $690.3M
- Insider buysLast 90 days, $10.3M in total
- 1
- Insider sellsLast 90 days, $2.25M in total
- 1
- 13F holdersQ3 2026, +65 vs. previous quarter
- 65
- 13F valueReported value at the end of Q3 2026
- $693.4M
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, Q3 FY2026
- $0
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 1.59M
- Shares sold short
- Change
- +134.4K
- +9.3% vs. previous
- Days to cover
- 4.50
- At average daily volume
Superinvestors holding ATTO, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding ATTO at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Attovia Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 28, 2026 (view filing)5:38 PM ET | Aug 5-6 | 23 days | Walsh ColinDirector | PPurchase | +585.0K | $17.58 | +$10.3M | +24.0%3.02M after | Amended2 lotsDuplicate filing |
| Aug 28, 2026 (view filing)5:38 PM ET | Aug 5 | 23 days | Walsh ColinDirector | SSale | −105.8K | $21.28 | −$2.25M | −100.0%0 after | Amended23 lotsDuplicate filing |
| Aug 28, 2026 (view filing)5:38 PM ET | Aug 5 | 23 days | Walsh ColinDirector | PPurchase | +105.8K | $21.25 | +$2.25M | –105.8K after | AmendedDerivative6 lotsDuplicate filing |
| Aug 28, 2026 (view filing)5:38 PM ET | Aug 5-6 | 23 days | Goldman Sachs & Co. LLC and 7 othersOther: Former 10% Owner | PPurchase | +585.0K | $17.58 | +$10.3M | +24.0%3.02M after | Amended2 lots |
| Aug 28, 2026 (view filing)5:38 PM ET | Aug 5 | 23 days | Goldman Sachs & Co. LLC and 7 othersOther: Former 10% Owner | SSale | −105.8K | $21.28 | −$2.25M | −100.0%0 after | Amended23 lots |
| Aug 28, 2026 (view filing)5:38 PM ET | Aug 5 | 23 days | Goldman Sachs & Co. LLC and 7 othersOther: Former 10% Owner | PPurchase | +105.8K | $21.25 | +$2.25M | –105.8K after | AmendedDerivative6 lots |
| Aug 10, 2026 (view filing)4:12 PM ET | Aug 6 | 4 days | venBio Global Strategic Fund IV, L.P.10% Owner | PPurchase | +382.4K | $17.00 | +$6.50M | +10.1%4.18M after | |
| Aug 7, 2026 (view filing)9:47 PM ET | Aug 6 | 1 day | Redmile Group, LLC and 2 others10% Owner | PPurchase | +200.0K | $17.00 | +$3.40M | +25.5%982.9K after | |
| Aug 7, 2026 (view filing)9:47 PM ET | Aug 6 | 1 day | Redmile Group, LLC and 2 others10% Owner | PPurchase | +400.0K | $17.00 | +$6.80M | +51.1%1.18M after | |
| Aug 7, 2026 (view filing)3:45 PM ET | Aug 6 | 1 day | Sanofi10% Owner | PPurchase | +300.0K | $17.00 | +$5.10M | +38.3%1.08M after |
Top 10 13F holders, Q3 2026
See all 65 holdersThe largest institutional positions in Attovia Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 7,046,271 | $120.8M | 3.00% | +7,046,271 | New |
| Goldman Sachs Group Inc | 5,391,772 | $92.4M | 0.01% | +5,391,772 | New |
| venBio Partners LLC | 4,181,366 | $71.7M | 14.45% | +4,181,366 | New |
| Deep Track Capital, LP | 3,207,138 | $55.0M | 0.93% | +3,207,138 | New |
| EcoR1 Capital, LLC | 2,024,010 | $34.7M | 1.71% | +2,024,010 | New |
| Nextech Invest, Ltd. | 1,835,139 | $31.5M | 1.41% | +1,835,139 | New |
| Cormorant Asset Management, LP | 1,788,815 | $30.7M | 2.06% | +1,788,815 | New |
| Redmile Group, LLC | 1,163,587 | $19.9M | 1.46% | +1,163,587 | New |
| Commodore Capital LP | 1,160,000 | $19.9M | 1.54% | +1,160,000 | New |
| Sanofi | 1,082,855 | $18.6M | 2.95% | +1,082,855 | New |
Holders of 5% or more of ATTO
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Attovia Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Frazier Life Sciences Public Fund, L.P. | 13D | 13.50%6.15M shares | New | Aug 11, 20261 filing | Aug 11, 2026 | SEC |
| venBio Global Strategic Fund IV, L.P. | 13G | 9.20%4.18M shares | New | Nov 16, 20261 filing | Nov 16, 2026 | SEC |
| Deep Track Capital, LP | 13G | 7.45%3.21M shares | New | Aug 12, 20261 filing | Aug 12, 2026 | SEC |
| Alamar HoldCo, LLC | 13G | 7.10%3.23M shares | New | Nov 13, 20261 filing | Nov 13, 2026 | SEC |
| Goldman Sachs Group Inc | 13G | 6.70%3.04M shares | New | Nov 13, 20261 filing | Nov 13, 2026 | SEC |